Wet age-related macular degeneration (wAMD)
Conditions
Brief summary
The primary endpoint of this study is to find out whether EYP-1901 can produce the same vision benefits as aflibercept over 56 weeks.
Detailed description
The secondary endpoints of the study are to find out: 1. Total number of supplemental injections of aflibercept needed over the 56 weeks of treatment, 2. Changes in the thickness of the retina (light-sensitive membrane at the back of the eye) from Week 12 through Week 56 of treatment, 3. Number of injections a participant needs up to 96 weeks of treatment, 4. Changes in the retina structure and function over the 96 weeks of treatment
Interventions
DRUGEYP-1901
DRUGEylea 40 mg/mL solution for injection in pre-filled syringe.
Sponsors
Eyepoint Pharmaceuticals Inc.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint of this study is to find out whether EYP-1901 can produce the same vision benefits as aflibercept over 56 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoints of the study are to find out: 1. Total number of supplemental injections of aflibercept needed over the 56 weeks of treatment, 2. Changes in the thickness of the retina (light-sensitive membrane at the back of the eye) from Week 12 through Week 56 of treatment, 3. Number of injections a participant needs up to 96 weeks of treatment, 4. Changes in the retina structure and function over the 96 weeks of treatment | — |
Countries
Czechia, Germany, Hungary, Poland, Slovakia
Outcome results
None listed